- increased T cell number / IMPC
- hyperactivity / IMPC
- decreased hemoglobin content / IMPC
- abnormal glucose homeostasis / IMPC
- thrombocytosis / IMPC
- decreased hematocrit / IMPC
- decreased circulating cholesterol level / IMPC
- decreased IgG3 level / IMPC
- decreased mature B cell number / IMPC
- decreased circulating free fatty acids level / IMPC
- increased IgM level / IMPC
- increased IgG1 level / IMPC
- decreased circulating triglyceride level / IMPC
- decreased bone mineral density / IMPC
- increased IgG2b level / IMPC
- decreased erythrocyte cell number / IMPC
C57BL/6N-Plcg2em1(IMPC)Wtsi/WtsiCnbc
Status | Available to order |
EMMA ID | EM:13892 |
International strain name | C57BL/6N-Plcg2em1(IMPC)Wtsi/WtsiCnbc |
Alternative name | |
Strain type | Endonuclease-mediated |
Allele/Transgene symbol | Plcg2em1(IMPC)Wtsi |
Gene/Transgene symbol | Plcg2 |
Information from provider
Provider | Wellcome Trust Sanger Institute |
Provider affiliation | Wellcome Trust Sanger Institute |
Genetic information | This mouse line originates from CRISPR zygote microinjection. For further details see the project page at the IMPC portal. |
Phenotypic information | Potential phenotyping data in the IMPC portal |
References | None available |
Information from EMMA
Archiving centre | CNB-CSIC, Centro Nacional de Biotecnologia, Madrid, Spain |
Animals used for archiving | heterozygous C57BL/6N |
Disease and phenotype information
Orphanet associated rare diseases, based on orthologous gene matching
- PLCG2-associated antibody deficiency and immune dysregulation / Orphanet_300359
- Autoinflammation-PLCG2-associated antibody deficiency-immune dysregulation / Orphanet_324530
IMPC phenotypes (gene matching)
MGI phenotypes (gene matching)
- abnormal trabecular bone morphology / MGI
- abnormal foot pad morphology / MGI
- spleen hyperplasia / MGI
- dermatitis / MGI
- internal hemorrhage / MGI
- abnormal humoral immune response / MGI
- arrested B cell differentiation / MGI
- decreased IgM level / MGI
- abnormal inflammatory response / MGI
- abnormal lymphatic vessel morphology / MGI
- premature death / MGI
- abnormal B cell differentiation / MGI
- abnormal dendritic cell physiology / MGI
- increased susceptibility to viral infection / MGI
- abnormal B cell physiology / MGI
- chronic inflammation / MGI
- glomerulonephritis / MGI
- increased pre-B cell number / MGI
- decreased susceptibility to induced arthritis / MGI
- osteoarthritis / MGI
- decreased osteoclast cell number / MGI
- impaired natural killer cell mediated cytotoxicity / MGI
- decreased B cell proliferation / MGI
- increased B cell proliferation / MGI
- immune system phenotype / MGI
- abnormal dendritic cell morphology / MGI
- decreased B-1a cell number / MGI
- decreased follicular B cell number / MGI
- increased pro-B cell number / MGI
- decreased transitional stage B cell number / MGI
- decreased B-2 B cell number / MGI
- decreased mature B cell number / MGI
- abnormal osteoclast differentiation / MGI
- decreased tumor necrosis factor secretion / MGI
- decreased interferon-gamma secretion / MGI
- increased B cell apoptosis / MGI
- increased trabecular bone thickness / MGI
- decreased platelet aggregation / MGI
- increased transitional stage T2 B cell number / MGI
- abnormal dendritic cell chemotaxis / MGI
- abnormal NK cell physiology / MGI
- increased trabecular bone volume / MGI
- chylous ascites / MGI
Information on how we integrate external resources can be found here
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).